LONDON: Haleon, the consumer health care unit spun off by United Kingdom drug giant GlaxoSmithKline (GSK), was worth about £31 billion ($36 billion) when it began trading in London on Monday.
The new company — which owns brands that include Sensodyne toothpaste, pain-relief drug Panadol and cold treatment Theraflu — was worth lower than an expected £40 billion, with its shares down 5 percent.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.